

On behalf of: Par Pharmaceutical, Inc.

Entered: June 3, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PAR PHARMACEUTICAL, INC.  
*Petitioner*

v.

NOVARTIS AG.  
*Patent Owner*

---

Case IPR2016-01059  
U.S. Patent No. 5,665,772

---

Before PATRICK E. BAKER, *Trial Paralegal*.

**PETITIONER'S TRANSMITTAL LETTER  
ACCOMPANYING SUBMISSION OF EXHIBIT 1031**

Case IPR2016-01059  
U.S. Patent No. 5,665,772

Pursuant to 37 C.F.R. § 42.6(e)(4)(ii) and the Board's June 2, 2016 Order (Paper 6), Petitioner Par Pharmaceutical, Inc. respectfully submits the following exhibit.

<b>Exhibit</b>	<b>Description</b>
1031	Transcript of June 1, 2016 Conference Call

Respectfully submitted,

Dated: June 3, 2016

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)  
Latham & Watkins LLP  
885 Third Avenue  
New York, NY 10022-4834  
212-906-1200; 212-751-4864 (Fax)

*Counsel for Petitioner  
Par Pharmaceutical, Inc.*

Case IPR2016-01059  
U.S. Patent No. 5,665,772

**CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 3rd day of June, 2016, true and correct copies of the foregoing **PETITIONER'S TRANSMITTAL LETTER ACCOMPANYING SUBMISSION OF EXHIBIT 1031; and EXHIBIT 1031** were served by Federal Express next business day delivery on Patent Owner's counsel:

Novartis Pharmaceutical Corporation  
Intellectual Property Department  
One Health Plaza 433/2  
East Hanover, NJ 07936-1080

Nicholas N. Kallas (Reg. No. 31,530)  
Raymond R. Mandra (Reg. No. 34,382)  
Fitzpatrick, Cella, Harper & Scinto  
1290 Avenue of the Americas  
New York, NY 10104-3800  
ZortressAfinitorIPR@fchs.com

via FEDERAL EXPRESS next business day delivery, on June 3, 2016

By: /Daniel G. Brown/

Daniel G. Brown (Reg. No. 54,005)  
Latham & Watkins LLP  
885 Third Avenue  
New York, NY 10022-4834  
212-906-1200; 212-751-4864 (Fax)

*Counsel for Petitioner*